Comparative Pharmacology
Head-to-head clinical analysis: DELTALIN versus DOXERCALCIFEROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DELTALIN versus DOXERCALCIFEROL.
DELTALIN vs DOXERCALCIFEROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Vitamin D analog; binds to vitamin D receptors, increasing intestinal absorption of calcium and phosphate, promoting renal tubular reabsorption of calcium, and enhancing bone mineralization.
Doxercalciferol is a synthetic vitamin D2 analog that undergoes hepatic conversion to its active metabolite, 1α,25-dihydroxyvitamin D2, which binds to the vitamin D receptor (VDR) in the parathyroid glands, reducing parathyroid hormone (PTH) synthesis and secretion. It also increases intestinal calcium and phosphate absorption and promotes bone mineralization.
0.5 mg orally once daily, titrated to a maximum of 1 mg daily based on response and tolerability.
0.5 mcg orally three times per week at each hemodialysis session; alternatively, 1 mcg orally three times per week. Intravenous: 0.5 mcg bolus three times per week at end of hemodialysis; titrate to target intact parathyroid hormone (iPTH) level.
None Documented
None Documented
Clinical Note
moderateDoxercalciferol + Hydrochlorothiazide
"Doxercalciferol may increase the hypercalcemic activities of Hydrochlorothiazide."
Clinical Note
moderateDoxercalciferol + Bendroflumethiazide
"Doxercalciferol may increase the hypercalcemic activities of Bendroflumethiazide."
Clinical Note
moderateDoxercalciferol + Methyclothiazide
"Doxercalciferol may increase the hypercalcemic activities of Methyclothiazide."
Clinical Note
moderateDoxercalciferol + Hydroflumethiazide
Terminal elimination half-life ranges from 24 to 36 hours in adults with normal renal function; may be prolonged (up to 72 hours) in renal impairment.
Terminal elimination half-life is approximately 96 hours (range 48–168 hours) in patients with chronic kidney disease, reflecting slow release from adipose tissue and prolonged vitamin D receptor activation.
Renal excretion of unchanged drug accounts for approximately 60-70% of the administered dose; biliary/fecal elimination accounts for 30-40%, primarily as metabolites.
Primarily fecal (biliary) elimination; renal excretion accounts for <2% of unchanged drug in urine.
Category C
Category A/B
Vitamin D Analog
Vitamin D Analog
"Doxercalciferol may increase the hypercalcemic activities of Hydroflumethiazide."